SGN-2FF

製品コードS9954 バッチS995402

印刷

化学情報

Synonyms

2-fluorofucose

Storage
(From the date of receipt)

3 years -20°C powder

化学式

C₆H₁₁FO₄

分子量

166.15

CAS No.

2089647-47-0

Solubility (25°C)*

体外

DMSO

33 mg/mL (198.61 mM)

Water

33 mg/mL (198.61 mM)

Ethanol

17 mg/mL (102.31 mM)

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	1.650mg/ml (9.93mM)	Taking the 1 mL working solution as an example, add 50 μL of 33 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	1.650mg/ml (9.93mM)	Taking the 1 mL working solution as an example, add 50 μL of 33 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	SGN-2FF（2-フルオロフコース）は、マウスモデルで有望な前臨床抗腫瘍活性を示した、経口生体利用可能なフコシルトランスフェラーゼの低分子阻害剤です。
in vitro	SGN‐2FF can fully inhibit the fucosylation of the h1F6 mAb at the lowest screening concentration in CHO cells treated with SGN‐2FF. The functional effect of inhibiting fucosylation of LS174T cells with SGN‐2FF is apparent from its diminished adherence to E-selectin–coated plates.
in vivo	In mice, SGN‐2FF inhibits fucosylation of endogenously produced antibodies, tumor xenograft membranes, and neutrophil adhesion glycans. SGN‐2FF treatment affords complete protection from tumor engraftment in a syngeneic tumor vaccine model, inhibits neutrophil extravasation, and delays the outgrowth of tumor xenografts in immune-deficient mice.

プロトコル(参考用のみ)

細胞アッセイ	細胞株	human LS174T colorectal cells, CHO cells
	濃度	100 μM
	反応時間	10 days
	実験の流れ	LS174T cells are cultured in Eagle MEM with 10% FBS with or without 100 μM SGN‐2FF for 10 d. LS174T xenografts from SGN‐2FF-treated or untreated mice are disaggregated by treatment with collagenase, and loose cells are collected. Cells from either source are washed with PBS solution containing 2% FBS and 0.02% sodium azide and stained with biotinylated LCA, cBR96-Alexa Fluor 488, or SSEAI–Alexa Fluor 488 (1 h on ice). Cells are washed and resuspended in PBS solution/FBS/sodium azide at 4 °C. The lectin-stained cells are treated with FITC-conjugated avidin D (30 min on ice), washed, and then analyzes by flow cytometry.
動物実験	動物モデル	Mouse
	投薬量	1 mM, 10 mM, 100 mM
	投与方法	i.g.

参考

https://pubmed.ncbi.nlm.nih.gov/34288257/
https://pubmed.ncbi.nlm.nih.gov/23493549/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

FUT8-Mediated Core Fucosylation Promotes the Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension [ Aging Dis, 2023, 14(5):1927-1944]	PubMed: 37196106

FUT8-Mediated Core Fucosylation Promotes the Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension [ Aging Dis, 2023, 14(5):1927-1944]

PubMed: 37196106

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。